We would urge the authorities to allow us the market authorisation so that we can strengthen our fight against Covid-19.” The development of VINCOV-19 by VINS Bio is an affirmation of “Aatmanirbhar Bharat” and the collaboration between the three partners is a step in the right direction. VINCOV-19 has been shown to be safe and ensures the speedy recovery of patients suffering from Covid-19. Speaking on the successful completion of the Phase-two clinical trials of VINCOV-19, Siddharth Daga, Chief Executive Officer, VINS Bioproducts Limited, said, “Phase-2 clinical trials of VINCOV-19 have been very successful. His expertise in immunological studies helped in the success of VINCOV-19 in clinical trials. Khan specializes in the area of immunology and Vaccinology. The UoH team is headed by Nooruddin Khan, an Associate Professor at the Department of Animal Biology, School of Life Sciences, University of Hyderabad. He said, “We are happy that we overcame all the uncertainties pertaining to the development of this product and are excited to see its success in clinical trials.” His group led the studies pertaining to the characterisation of the virus, antigen, and viral neutralisation assays.
Harshan at CCMB, isolated SARS-CoV-2 in April 2020, which led to this successful collaboration. It is a major step for the future targeted collaborations between academia and industry.” It is essential to have multiple options, including therapeutic antibodies, especially for severe clinical cases of Covid. Nandicoori, Director, CSIR-CCMB, said, “These therapeutic antibodies are the first in India and among the few around the globe. Rao, Vice-Chancellor, UoH, expressed happiness at this academia and industry collaboration with complementing technical and infrastructural strength available in the three partnering organisations yielding fruitful results in less than a year. Since neutralising antibodies could block the internalisation of SARS-CoV-2 to lung cells, it was postulated that their passive administration should render maximal clinical benefits if they are applied at the early stages of the disease.ī.J.
VINCOV-19 comprises highly purified F(ab’)2 antibody fragments that have a high neutralising capacity against the SARS-CoV-2 virus. VINCOV-19 contains Equine polyclonal antibodies (EpAbs) against the Covid-19 virus. There was a good and early improvement in the clinical condition of the patients administered VINCOV-19. VINCOV-19 showed an excellent safety profile in the Phase-two trials.
0 kommentar(er)
